Idazoxan partially reverses alpha-2 (α2)-inhibition of osmotic water permeability (Pf) in rat inner medulary collecting duct (IMCD)

A. Rouch, L. Kudo, C. Hébert

Research output: Contribution to journalArticle

Abstract

To determine if idazoxan would reverse α2-mediated inhibition of arginine vasopressin (AVP)-stimulated Pf in the terminal IMCD, Wistar rat IMCDs were isolated and perfused via standard methods and Pf was determined by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient. Two α2 agonists, clonidine and dexmedetomidine, were used in separate studies (n=5 each study) to induce inhibition of AVP-stimulated Pf. All agents were added to the bath: AVP at 220 pM; clonidine, dexmedetomidine, and idazoxan at 100 nM. Results (Pf μm/sec, mean±sel are shown below. Control AVP AVP+Ag AVP+Ag+Ida Ag=Clonidine 2±1 177±12 * 30±2 * 79±5 * Ag = Dex 7±3 169±10 * 22±1 * 38±5 1 * & † - significantly different from previous period (p<.001) and (p<.05), respectively. Ag - α2 agonist, Ida - idazoxan Idazoxan reversed clonidine- & dexmedetomidine-induced inhibition by 33% and 10%, respectively. In another set of experiments (n=5), the prototypical α2 antagonist yohimbine, reversed dexmedetomidine-induced inhibition of Pf by 50%, and in a previous study (Rouch, AJ et al. Am. J. Physiol. 271, F150-157, 1996) the α2 antagonist atipamezole reversed this inhibition ∼100%. These comparisons may lead to important information concerning different α2 adrenoceptor subtypes.

Original languageEnglish
Pages (from-to)A459
JournalFASEB Journal
Volume11
Issue number3
StatePublished - 1 Dec 1997

Fingerprint

Idazoxan
arginine vasopressin
Arginine Vasopressin
dexmedetomidine
Ducts
clonidine
Dexmedetomidine
Rats
Permeability
permeability
Clonidine
Water
rats
water
Baths
agonists
antagonists
yohimbine
Yohimbine
adrenergic receptors

Cite this

@article{44fd27c5f2c242839c4189bf95b426af,
title = "Idazoxan partially reverses alpha-2 (α2)-inhibition of osmotic water permeability (Pf) in rat inner medulary collecting duct (IMCD)",
abstract = "To determine if idazoxan would reverse α2-mediated inhibition of arginine vasopressin (AVP)-stimulated Pf in the terminal IMCD, Wistar rat IMCDs were isolated and perfused via standard methods and Pf was determined by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient. Two α2 agonists, clonidine and dexmedetomidine, were used in separate studies (n=5 each study) to induce inhibition of AVP-stimulated Pf. All agents were added to the bath: AVP at 220 pM; clonidine, dexmedetomidine, and idazoxan at 100 nM. Results (Pf μm/sec, mean±sel are shown below. Control AVP AVP+Ag AVP+Ag+Ida Ag=Clonidine 2±1 177±12 * 30±2 * 79±5 * Ag = Dex 7±3 169±10 * 22±1 * 38±5 1 * & † - significantly different from previous period (p<.001) and (p<.05), respectively. Ag - α2 agonist, Ida - idazoxan Idazoxan reversed clonidine- & dexmedetomidine-induced inhibition by 33{\%} and 10{\%}, respectively. In another set of experiments (n=5), the prototypical α2 antagonist yohimbine, reversed dexmedetomidine-induced inhibition of Pf by 50{\%}, and in a previous study (Rouch, AJ et al. Am. J. Physiol. 271, F150-157, 1996) the α2 antagonist atipamezole reversed this inhibition ∼100{\%}. These comparisons may lead to important information concerning different α2 adrenoceptor subtypes.",
author = "A. Rouch and L. Kudo and C. H{\'e}bert",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "11",
pages = "A459",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

Idazoxan partially reverses alpha-2 (α2)-inhibition of osmotic water permeability (Pf) in rat inner medulary collecting duct (IMCD). / Rouch, A.; Kudo, L.; Hébert, C.

In: FASEB Journal, Vol. 11, No. 3, 01.12.1997, p. A459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Idazoxan partially reverses alpha-2 (α2)-inhibition of osmotic water permeability (Pf) in rat inner medulary collecting duct (IMCD)

AU - Rouch, A.

AU - Kudo, L.

AU - Hébert, C.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - To determine if idazoxan would reverse α2-mediated inhibition of arginine vasopressin (AVP)-stimulated Pf in the terminal IMCD, Wistar rat IMCDs were isolated and perfused via standard methods and Pf was determined by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient. Two α2 agonists, clonidine and dexmedetomidine, were used in separate studies (n=5 each study) to induce inhibition of AVP-stimulated Pf. All agents were added to the bath: AVP at 220 pM; clonidine, dexmedetomidine, and idazoxan at 100 nM. Results (Pf μm/sec, mean±sel are shown below. Control AVP AVP+Ag AVP+Ag+Ida Ag=Clonidine 2±1 177±12 * 30±2 * 79±5 * Ag = Dex 7±3 169±10 * 22±1 * 38±5 1 * & † - significantly different from previous period (p<.001) and (p<.05), respectively. Ag - α2 agonist, Ida - idazoxan Idazoxan reversed clonidine- & dexmedetomidine-induced inhibition by 33% and 10%, respectively. In another set of experiments (n=5), the prototypical α2 antagonist yohimbine, reversed dexmedetomidine-induced inhibition of Pf by 50%, and in a previous study (Rouch, AJ et al. Am. J. Physiol. 271, F150-157, 1996) the α2 antagonist atipamezole reversed this inhibition ∼100%. These comparisons may lead to important information concerning different α2 adrenoceptor subtypes.

AB - To determine if idazoxan would reverse α2-mediated inhibition of arginine vasopressin (AVP)-stimulated Pf in the terminal IMCD, Wistar rat IMCDs were isolated and perfused via standard methods and Pf was determined by measuring net fluid flux in the presence of a lumen-to-bath osmotic gradient. Two α2 agonists, clonidine and dexmedetomidine, were used in separate studies (n=5 each study) to induce inhibition of AVP-stimulated Pf. All agents were added to the bath: AVP at 220 pM; clonidine, dexmedetomidine, and idazoxan at 100 nM. Results (Pf μm/sec, mean±sel are shown below. Control AVP AVP+Ag AVP+Ag+Ida Ag=Clonidine 2±1 177±12 * 30±2 * 79±5 * Ag = Dex 7±3 169±10 * 22±1 * 38±5 1 * & † - significantly different from previous period (p<.001) and (p<.05), respectively. Ag - α2 agonist, Ida - idazoxan Idazoxan reversed clonidine- & dexmedetomidine-induced inhibition by 33% and 10%, respectively. In another set of experiments (n=5), the prototypical α2 antagonist yohimbine, reversed dexmedetomidine-induced inhibition of Pf by 50%, and in a previous study (Rouch, AJ et al. Am. J. Physiol. 271, F150-157, 1996) the α2 antagonist atipamezole reversed this inhibition ∼100%. These comparisons may lead to important information concerning different α2 adrenoceptor subtypes.

UR - http://www.scopus.com/inward/record.url?scp=33750248708&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750248708

VL - 11

SP - A459

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -